<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75550">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905644</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2012/VL-01</org_study_id>
    <secondary_id>2013-A00773-42</secondary_id>
    <nct_id>NCT01905644</nct_id>
  </id_info>
  <brief_title>Verifying Post-delivery Anal Sphincter Integrity Using Perineal Ultrasound: Impact on Immediate Care</brief_title>
  <acronym>OASIS 2</acronym>
  <official_title>Verifying Anal Sphincter Integrity in the Delivery Room Using a Specific Perineal Ultrasound: Impact on Immediate Care and Postpartum Anal Incontinence Rates in Mothers Undergoing Vaginal Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare post partum rates of anal sphincter rupture
      (that is to say the rate of sutures) diagnosed in women with ≥ 2nd degree vaginal tears
      between two groups: (1) women who are screened just after delivery by performing a perineal
      ultrasound versus a similar group of women who did not receive screening. This study was not
      designed to evaluate ultrasound as a diagnostic test but to compare the rate of perineal
      surgical procedures in each arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:

      A. Compare the anal incontinence score (measured by the Wexner score, qualitative and
      quantitative assessment) at 3 months between the two groups.

      B. To assess the safety of perineal ultrasound in the group with &quot;ultrasound&quot; using a visual
      analog scale for discomfort

      C. Assess the  inter and intra operator consistency of perineal ultrasound snapshot readings

      D. Evaluate and compare the rate of infectious complications of perineal sutures between the
      two groups at 3 months.

      E. Evaluate and compare the quality of life (questionnaires PFIQ, PFDI, SF36, Euroqol)
      between the two groups at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Presence/absence of an anal sphincter rupture</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wexner score for anal incontinence</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wexner score for anal incontinence</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of perineal ultrasound</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual analog scale (0 to 10) used to evaluate discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kappa coefficient for inter-operator ultrasound reading</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kappa coefficient for intra-operator ultrasound reading</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of suture infection</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFIQ questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFIQ questionnaire</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFDI questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFDI questionnaire</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol questionnaire</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol questionnaire</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Delivery, Obstetric</condition>
  <arm_group>
    <arm_group_label>With ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.
Intervention:  Perineal ultrasound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without ultrasound</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Perineal ultrasound</intervention_name>
    <description>Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.</description>
    <arm_group_label>With ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given her informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is available for 3 months of follow-up

          -  Paturient, vaginal births only

          -  Presence of &gt;= stage 2 perineal lesion

          -  Patient accepts a priori the performance of a perineal ultrasound

        Exclusion Criteria:

          -  The patient is participating in another study (excepting BBBOX (2011-A00327-36),
             ElastoMAP (2013-A01148-37) and &quot;scalp lactates&quot; studies at the Nîmes University
             Hospital)

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  Delivery by C-section

          -  Intact perineum after delivery (no indication for perineal surgery in light of
             absence of vaginal lesion)

          -  Emergency situation preventing time for perineal ultrasound

          -  History of anal incontinence before giving birth

          -  Allergy to ultrasound gel
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Letouzey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Letouzey, MD</last_name>
    <phone>+33.(0)4.66.68.32.16</phone>
    <email>vincent.letouzey@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anaig Flandrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Boulot, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Letouzey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Pouget, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eve Mousty, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud de Tayrac, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Marès, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Bourgaux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier Fritel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie Brossard-Violeau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaginal delivery</keyword>
  <keyword>Perineal lesions</keyword>
  <keyword>Anal sphincter rupture</keyword>
  <keyword>Ultrasound</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
